Modelling during drug development

Author： Balant L.P.   Gex-Fabry M.  

Publisher： Elsevier

ISSN： 0939-6411

Source： European Journal of Pharmaceutics and Biopharmaceutics, Vol.50, Iss.1, 2000-07, pp. : 13-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Modelling Anxiety in Humans for Drug Development

By  

Current Neuropharmacology, Vol. 5, Iss. 1, 2007-03 ,pp. : 65-72

Bentham Science Publishers

Access to resources Recommend Favorite

Modelling neurodegeneration in prion disease – applications for drug development

By Uppington Kay M   Brown David R  

Expert Opinion on Drug Discovery, Vol. 2, Iss. 6, 2007-06 ,pp. : 777-788

Informa Healthcare

Access to resources Recommend Favorite

Role of modelling and simulation in Phase I drug development

By Aarons L.   Karlsson M.O.   Mentre F.   Rombout F.   Steimer J.-L.   van Peer A.   invited COST B15 Experts  

European Journal of Pharmaceutical Sciences, Vol. 13, Iss. 2, 2001-05 ,pp. : 115-122

Elsevier

Access to resources Recommend Favorite

Evaluating the QT-Liability of a Drug during its Development

By Shah Rashmi R.  

Pharmaceutical Medicine, Vol. 22, Iss. 3, 2008-01 ,pp. : 151-164

Adis International

Access to resources Recommend Favorite

Detection and management of nephrotoxicity during drug development

By Loghman-Adham Dr Mahmoud   Kiu Weber Dr Chek Ing   Ciorciaro Dr Cornelia   Mann Dr Jessica   Meier Dr Matthias  

Expert Opinion on Drug Safety, Vol. 11, Iss. 4, 2012-07 ,pp. : 581-596

Informa Healthcare

Access to resources Recommend Favorite